Rabbit Polyclonal SF3B3 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 6 publications. Immunogen corresponding to Synthetic Peptide within Human SF3B3 aa 1150 to C-terminus.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 78.99% PBS, 20% Glycerol (glycerin, glycerine), 1% BSA
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Mouse | Predicted | Predicted |
Zebrafish | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 - 1/3000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Zebrafish | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/250 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Zebrafish | Dilution info - | Notes - |
Select an associated product type
Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs (PubMed:10490618, PubMed:10882114, PubMed:12234937, PubMed:27720643, PubMed:28781166, PubMed:32494006, PubMed:34822310). The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing (PubMed:12234937, PubMed:32494006, PubMed:34822310). Within the 17S U2 SnRNP complex, SF3B3 is part of the SF3B subcomplex, which is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA (PubMed:12234937, PubMed:27720643). Sequence independent binding of SF3A and SF3B subcomplexes upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA (PubMed:12234937). May also be involved in the assembly of the 'E' complex (PubMed:10882114). Also acts as a component of the minor spliceosome, which is involved in the splicing of U12-type introns in pre-mRNAs (PubMed:15146077, PubMed:33509932).
KIAA0017, SAP130, SF3B3, Splicing factor 3B subunit 3, Pre-mRNA-splicing factor SF3b 130 kDa subunit, STAF130, Spliceosome-associated protein 130, SF3b130, SAP 130
Rabbit Polyclonal SF3B3 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 6 publications. Immunogen corresponding to Synthetic Peptide within Human SF3B3 aa 1150 to C-terminus.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 78.99% PBS, 20% Glycerol (glycerin, glycerine), 1% BSA
SF3B3 also known as SAP130 is a component of the splicing factor 3b complex vital for pre-mRNA processing. It is approximately 130 kDa in mass and prominently expressed across various tissue types including the liver lungs and heart. SF3B3 functions in the spliceosome a complex machinery essential for the removal of introns from pre-mRNA transcripts.
SF3B3 participates in the assembly and stabilization of the functional spliceosomal complex. It is a part of the larger SF3b complex which is critical for recognizing the branch point sequence in RNA during splicing. This recognition influences the selection of splice sites and impacts the regulation of alternative splicing events. The SF3b complex works with the U2 small nuclear ribonucleoprotein (snRNP) during the splicing process to ensure accurate and efficient mRNA maturation.
SF3B3 plays a significant role in the splicing pathway and impacts gene expression regulation through alternative splicing. It works alongside proteins such as SF3B1 and other splicing factors maintaining proper cellular function by influencing transcript variants. Another important pathway involving SF3B3 is RNA transport where it assists in the export of mature and correctly processed mRNA from the nucleus to the cytoplasm.
SF3B3 is closely linked to myelodysplastic syndromes and certain types of cancer such as breast cancer. Mutations or dysregulation of SF3B3 can result in aberrant splicing patterns contributing to tumorigenesis and disease progression. The protein is often studied along with SF3B1 as both are part of the splicing machinery and have been implicated in splicing-related genetic abnormalities that drive these disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
5% SDS-PAGE
All lanes: Western blot - Anti-SF3B3 antibody (ab96683) at 1/3000 dilution
All lanes: HeLa whole cell lysate at 30 µg
Predicted band size: 136 kDa
ab96683, at 1/100 dilution, staining SF3B3 in paraffin-embedded Saos-2 by Immunohistochemistry.
Image collected and cropped by CiteAb under a CC-BY license from the publication
SF3B3 western blot using anti-SF3B3 antibody ab96683. Publication image and figure legend from Chakraborty, P., Huang, J. T. J., et al., 2018, Nat Commun, PubMed 30341290.
ab96683 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab96683 please see the product overview.
DHX9 helicase activity is required for R-loop formation and growth inhibition. a Expression of wild-type DHX9, but not a helicase-defective mutant (pGFP-DHX9dead), promotes R-loop formation in SFPQ-defective cells. Fluorescence intensity of S9.6 staining was measured for n > 50 cells. Statistical significance was determined using Mann–Whitney test (****p < 0.0001). b Expression of wild-type DHX9 but not a helicase-defective mutant confers impaired cell proliferation in SFPQ-depleted cells (siSFPQ8). Cell number was measured using a Casey Cell Counter 48 h after transfection with siRNA (time 0) and again after 3, 5, and 7 days. c RNA Pol II S2P was immunoprecipitated from Hela cell nuclear extracts and co-purification of different splicing factors was probed by western blot (as indicated). Duplicate samples were treated with RNaseA as indicated to demonstrate the requirement of RNA in these interactions
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com